JP2023532129A5 - - Google Patents
Info
- Publication number
- JP2023532129A5 JP2023532129A5 JP2022581401A JP2022581401A JP2023532129A5 JP 2023532129 A5 JP2023532129 A5 JP 2023532129A5 JP 2022581401 A JP2022581401 A JP 2022581401A JP 2022581401 A JP2022581401 A JP 2022581401A JP 2023532129 A5 JP2023532129 A5 JP 2023532129A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- domain
- mutation
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046477P | 2020-06-30 | 2020-06-30 | |
| US63/046,477 | 2020-06-30 | ||
| PCT/US2021/039961 WO2022006316A1 (en) | 2020-06-30 | 2021-06-30 | Multi-specific antibodies binding to bcma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025272312A Division JP2026071208A (ja) | 2020-06-30 | 2025-12-22 | Ｂｃｍａに結合する多重特異性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532129A JP2023532129A (ja) | 2023-07-26 |
| JP2023532129A5 true JP2023532129A5 (https=) | 2024-06-25 |
Family
ID=77127069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581401A Pending JP2023532129A (ja) | 2020-06-30 | 2021-06-30 | Ｂｃｍａに結合する多重特異性抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230257473A1 (https=) |
| EP (1) | EP4171750A1 (https=) |
| JP (1) | JP2023532129A (https=) |
| KR (1) | KR20230038211A (https=) |
| CN (1) | CN116472049A (https=) |
| AU (1) | AU2021300179A1 (https=) |
| BR (1) | BR112022027101A2 (https=) |
| CA (1) | CA3189297A1 (https=) |
| CL (1) | CL2022003754A1 (https=) |
| CO (1) | CO2023000808A2 (https=) |
| CR (2) | CR20220656A (https=) |
| IL (1) | IL299027A (https=) |
| JO (1) | JOP20220357A1 (https=) |
| MX (1) | MX2022016342A (https=) |
| PE (1) | PE20230464A1 (https=) |
| WO (1) | WO2022006316A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| EP4611163A4 (en) | 2022-12-02 | 2025-11-26 | Lg Energy Solution Ltd | BATTERY BLOCK AND ITS MANUFACTURING PROCESS |
| WO2025010477A1 (en) * | 2023-07-13 | 2025-01-16 | Telix Pharmaceuticals (Innovations) Pty Ltd | Humanised antibodies and uses thereof |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| MX2018002043A (es) | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| WO2018224660A1 (en) * | 2017-06-09 | 2018-12-13 | Armin Ehninger | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders |
| KR20250007003A (ko) * | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN110945026B (zh) * | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| EP3581200A1 (en) * | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
-
2021
- 2021-06-30 CN CN202180052312.5A patent/CN116472049A/zh active Pending
- 2021-06-30 MX MX2022016342A patent/MX2022016342A/es unknown
- 2021-06-30 PE PE2022003030A patent/PE20230464A1/es unknown
- 2021-06-30 EP EP21748714.9A patent/EP4171750A1/en active Pending
- 2021-06-30 KR KR1020237003291A patent/KR20230038211A/ko active Pending
- 2021-06-30 CR CR20220656A patent/CR20220656A/es unknown
- 2021-06-30 WO PCT/US2021/039961 patent/WO2022006316A1/en not_active Ceased
- 2021-06-30 US US18/002,472 patent/US20230257473A1/en active Pending
- 2021-06-30 IL IL299027A patent/IL299027A/en unknown
- 2021-06-30 CA CA3189297A patent/CA3189297A1/en active Pending
- 2021-06-30 JP JP2022581401A patent/JP2023532129A/ja active Pending
- 2021-06-30 BR BR112022027101A patent/BR112022027101A2/pt unknown
- 2021-06-30 AU AU2021300179A patent/AU2021300179A1/en active Pending
- 2021-06-30 CR CR20250505A patent/CR20250505A/es unknown
-
2022
- 2022-12-26 CL CL2022003754A patent/CL2022003754A1/es unknown
- 2022-12-29 JO JOJO/P/2022/0357A patent/JOP20220357A1/ar unknown
-
2023
- 2023-01-25 CO CONC2023/0000808A patent/CO2023000808A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532129A5 (https=) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2022551969A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2020062036A5 (https=) | ||
| JP2020180158A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2023106433A5 (https=) | ||
| JP2020511947A5 (https=) | ||
| JP2021533169A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2023123726A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2021511807A5 (https=) | ||
| JP2024537779A5 (https=) | ||
| JP2018533371A5 (https=) | ||
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2019501883A5 (https=) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2017534646A5 (https=) | ||
| JP2020529410A5 (https=) | ||
| JP2017533694A5 (https=) | ||
| JP2020519308A5 (https=) | ||
| JP2023548529A5 (https=) |